sipuleucel-T + abiraterone acetate

**Sipuleucel-T + abiraterone acetate** is an investigational combination regimen used for treating **metastatic castration-resistant prostate cancer (mCRPC)**. Sipuleucel-T is an autologous cellular immunotherapy (a dendritic cell vaccine) that stimulates the patient's immune system to target prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers. Abiraterone acetate is a small molecule inhibitor of CYP17A1, an enzyme critical for androgen biosynthesis; it reduces androgen production in the testes, adrenals, and prostate tumor tissue, thus inhibiting tumor growth dependent on androgens[2][3][4]. Clinical studies (STAMP, NCT01487863) demonstrated that **sipuleucel-T can be administered concurrently or sequentially with abiraterone acetate (typically plus prednisone) without compromising immunologic response or efficacy**[1][2][3]. Sipuleucel-T induces a robust immune prime-boost effect, and the combination yields similar median overall survival compared with monotherapy. The combination is generally well tolerated with a safety profile consistent with each agent individually[1][2][3][4].

Other names

sipuleucel-T + abiraterone acetate